Actuate Therapeutics Inc
NASDAQ:ACTUBiotechnology
+$0.06 today
- Market cap
- $50.01M
- Beta
- 0.53
- P/E (TTM)
- -2.3
- EPS (TTM)
- -$0.92
Volume 0.03M
Average 0.16M
ACTU Other Non-current Liabilities
Long-term obligations not reported separately, such as lease or pension liabilities.
Actuate Therapeutics IncNASDAQ: ACTU
Other Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other non-current liabilities remains negative
Q1 FY2026 other non-current liabilities was $0, compared with $416.82K a year earlier.
Context
- Other non-current liabilities amounted to 0.0% of total assets at the end of Q1 FY2026, down 9.3 pp from a year earlier.
- Other non-current liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether other non-current liabilities keeps falling in the next quarterly balance sheet after a -100.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Other Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | -100.0% |
| FY2024 | 2024-12-31 | 411.76K | -99.6% |
| FY2023 | 2023-12-31 | 95.7M | +10524.5% |
| FY2022 | 2022-12-31 | 900.76K | — |
Other Non-current Liabilities vs competitors
How ACTU compares with its peers on the latest reported figures
- Peers report in different currencies, so other non-current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -100.0% is the lowest of 6, against a peer median of +21.5%.
- Other non-current liabilities amounts to 0.0% of total assets for ACTU, versus a peer median of 1.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $638.46M USD | — | — | 126.0% | |
| Mar 2026 | CHF 8.25M CHF | +173.2% | +48.2% | 9.4% | |
ELTXElicio Therapeutics, Inc. | Mar 2026 | $3.6M USD | +21.5% | +205.2% | 15.9% |
| Mar 2026 | $2.14M USD | +13.0% | +12.9% | 1.8% | |
| Mar 2026 | $1.77M USD | +27.0% | +31.8% | 0.7% | |
| Mar 2026 | $91K USD | — | -1.8% | 0.2% | |
| Mar 2026 | $87K USD | +0.0% | — | 0.0% | |
ACTUActuate Therapeutics Inc | Mar 2026 | $0 USD | -100.0% | — | 0.0% |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding ACTU) | — | +21.5% | +31.8% | 1.3% | |
Competitors are the stored peer set for ACTU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Actuate Therapeutics Inc
NASDAQ:ACTU
Intrinsic Alpha fair value
Locked
Current Price
$2.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.